Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03425-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Tianqi An und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Quinolines, Biliary Tract Neoplasms, Indoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of HPB Surgery, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
- Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, China.
- Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Respiratory Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- Department of Integrated Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyylijia4420@zzu.edu.cn.
Zitieren
APA
An, T., Hui, Q., Zong, H., Liu, L., Cao, X., Li, R., Hu, S., Liu, Y., Li, J., & Zhao, R. (2024). Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03425-4
Vancouver
An T, Hui Q, Zong H, Liu L, Cao X, Li R, et al. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03425-4
BibTeX
@article{An2024,
author = {An, Tianqi and Hui, Qiu and Zong, Hong and Liu, Linhua and Cao, Xinguang and Li, Rui and Hu, Shuang and Liu, Yiyi and Li, Jia and Zhao, Ruihua},
title = {Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03425-4}
}
EUVIMED